Innate Pharma announces publication of IPH4102 Phase I clinical trial results for CTCL in the Lancet Oncology
(WorldNews Europe)

Data to date demonstrate high activity and favorable safety profile in Sézary syndrome, an aggressive form of cutaneous T-cell lymphoma (CTCL) International IPH4102 TELLOMAK Phase II clinical trial in advanced T-cell lymphoma (TCL) launched in June 2019 Innate Pharma SA (the `Company` - Euronext Paris:...